Mast cell development in mice is critically regulated by stem cell factor (SCF), the term used here to designate a product of fibroblasts and other cell types that is a ligand for the tyrosine kinase receptor protein encoded by the proto-oncogene c-kit. However, the factors which regulate the size of mast cell populations in primates are poorly understood. Here we report that the subcutaneous administration of recombinant human SCF (rhSCF) to baboons (Papio cynocephalus) or cynomolgus monkeys (Macaca fascicularis) produced a striking expansion of mast cell populations in many anatomical sites, with numbers of mast cells in some organs of rhSCF-treated monkeys exceeding the corresponding values in control monkeys by more than 100-fold. Animals treated with rhSCF did not exhibit clinical evidence of mast cell activation, and discontinuation of treatment with rhSCF resulted in a rapid decline of mast cell numbers nearly to baseline levels. These findings are the first to demonstrate that a specific cytokine can regulate mast cell development in primates in vivo. They also provide the first evidence, in any mammalian species, to indicate that the cytokinedependent expansion of tissue mast cell populations can be reversed when administration of the cytokine is discontinued. (J.
Introduction
Mast cell development has been analyzed in more detail in mice than in any other species (for review see references [1] [2] [3] [4] . This work has demonstrated that mast cells are derived from precursors which arise in the bone marrow, circulate in the blood, and mature in virtually all vascularized tissues (1) (2) (3) (4) . Several aspects of mast cell development in mice are critically regulated by a growth factor, herein designated stem cell factor (SCF) l (5-7), which represents a ligand for the tyrosine kinase receptor encoded by the proto-oncogene c-kit (5) (6) (7) (8) (9) (10) . Thus, we showed that the subcutaneous administration of recombinant rat SCF'64 not only locally repaired the profound mast cell deficiency expressed by WCB6F,-Sl/Sld mice (7) , which have mutations at the Sl locus that encodes SCF (2, 4) , but also resulted in a significant (up to 150-fold) expansion of mast cell populations at the injection site in normal mice ( 11 ) . Evidence from in vivo (7, 1 1 ) and in vitro ( 12) studies indicates that the SCF-dependent expansion of mast cell populations in mice reflects the ability of this cytokine to induce mast cell proliferation and to promote mast cell survival and maturation. SCF also can increase the numbers of mast cell precursors which migrate to and/or survive at sites of SCF administration in vivo (7, 11) , perhaps in part by promoting the c-kit receptor-dependent attachment of mast cell precursors to these sites ( 13 ).
Despite great progress in our understanding of mast cell development in mice, it has been difficult to identify cytokines which regulate mast cell development in man and other primates (for review see reference 14) . Certain cytokines which clearly influence the development of some mast cell populations in mice, such as IL-3 and IL-4, have little or no effect on human mast cell development in vitro (for review see reference 14) . By contrast, coculture of human umbilical cord blood leukocytes with fibroblasts augments mast cell development in vitro ( 14) . Although fibroblasts represent a potential source of SCF (5) (6) (7) (8) (9) (10) , the effects of SCF on human mast cell development in vitro may vary significantly, depending on the details of the experiment. For example, preliminary evidence indicates that recombinant human SCF (rhSCF) promotes the preferential growth of mast cells from human umbilical cord blood cells ( 15) (Fig. 1 and Fig. 2 a-p) . The increases in mast cells compared to values in vehicle-treated control animals were especially prominent in the skin at the injection site (Fig. 2 a vs (Fig. 2 o vs. 2 p) , where in some areas mast cells appeared to occupy much of the available space in the lamina propria (Fig. 2 p) . When the mast cell content of these organs was expressed as the number of mast cells per square millimeter, the values in animals treated with rhSCF at 6.0 mg/kg per d were 11-to 1,500-fold those in the control monkeys treated with vehicle ( Fig. 1) . Striking mast cell hyperplasia also occurred in certain tissues of monkeys treated with rhSCF at 100 Ag/kg per d. Mast cell numbers in these animals were elevated 128-fold in the spleen, 20-fold in the liver, and three-to sevenfold in the dermis at the injection site, mesenteric lymph nodes, and the bone marrow (Fig. 1 ) . At least three factors may have contributed to the differences in the effects of treatment with rhSCF on mast cell numbers in different tissues: variation in the numbers of mast cells or their precursors in different anatomical sites at the start of treatment, the nature of the organ's vasculature, and the effects of other cytokines. Studies in mice ( 1-4) and humans ( 14, 15, 17) , indicate that the bone marrow represents a source of mast cell precursors; certain other organs, such as the skin and gastric mucosa, normally contain relatively large numbers of mature mast cells (see values for vehicle-treated monkeys in Fig.  1 ). Organs that have sinusoids or capillaries with a discontinuous endothelial cell lining, such as the liver, spleen, and bone marrow (21) , would be expected to develop relatively high interstitial levels of SCF upon systemic administration; this type of vasculature might also favor egress of circulating mast cell precursors or mast cells. Although morphologically identifiable mast cells ordinarily are not detectable in the circulation of mammals ( 1-4), mast cells were present within the lumens of occasional blood vessels in the liver (Fig. 2 j) or lungs ( Fig. 2 1 ) of monkeys treated with 6.0 mg rhSCF/kg per d. This finding, which was not observed in vehicle-treated control monkeys, indicates that treatment with rhSCF not only increased mast cell levels in the bone marrow, but also resulted in the appearance of mast cells in the peripheral blood. We found that both primates (this study) and rats ( 11 ) treated with SCF developed striking relative increases in mast cell numbers in the spleen, liver, and bone marrow. By contrast, the midbrain of monkeys treated with rhSCF exhibited no detectable mast cells. Not only does this site ordinarily lack a significant population of mast cells (no mast mast cells were observed in the midbrain specimens from vehicle-treated animals), but the vasculature ofthe central nervous system is relatively impermeable to macromolecules (21) . Finally, SCF exhibits synergistic effects with several hematopoietic cytokines in vitro (5) 
